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To date, 400 clinical trials concern acute 
ischemic stroke, of which >270 are considered 
to be complete (http://www.strokecenter.org/
trials). Although >1,000 molecules were shown 
to display neuroprotective effects in animal mod-
els of stroke, none of them has proved efficient 
when submitted to clinical trials (O’Collins et al., 
2006). This admission of failure illustrates the 
current difficulty to translate animal investiga-
tions into successful treatments for human stroke 
therapy. Such failure likely results from the way 
animal studies have been designed and how re-
sults are interpreted (Young et al., 2007). In fact, 
clear discrepancies exist between experimental 
studies and the actual clinical situation.
For instance, most of the experimental stud-
ies are conducted in young animals, although 
stroke generally occurs in aged patients, making 
aging the principal risk factor for this disease. 
Nevertheless, therapeutic strategies that protect 
young  tissues  are  not  necessarily  efficient  in 
older subjects. It is thus crucial to take the age 
factor into account in animal studies.
Also, although white matter tissues are af-
fected in most cases of stroke in human, account-
ing for half of the lesion volume (Ho et al., 
2005), they have largely been neglected in most 
animal studies (Arai and Lo, 2009). Because 
gray matter and white matter are very different 
in their structure and cellular content, the 
mechanisms leading to their degeneration after 
cerebral ischemia are distinct from each other. 
Thus, drugs which protect gray matter are not 
necessarily efficient in saving white matter. This 
could explain, in part, the failure of stroke clini-
cal trials (Dewar et al., 1999). For this reason, 
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Tissue plasminogen activator (tPA) is the only available treatment for acute stroke. In addi-
tion to its vascular fibrinolytic action, tPA exerts various effects within the brain, ranging 
from synaptic plasticity to control of cell fate. To date, the influence of tPA in the ischemic 
brain has only been investigated on neuronal, microglial, and endothelial fate. We addressed 
the mechanism of action of tPA on oligodendrocyte (OL) survival and on the extent of white 
matter lesions in stroke. We also investigated the impact of aging on these processes. We 
observed that, in parallel to reduced levels of tPA in OLs, white matter gets more susceptible 
to ischemia in old mice. Interestingly, tPA protects murine and human OLs from apoptosis 
through an unexpected cytokine-like effect by the virtue of its epidermal growth factor–like 
domain. When injected into aged animals, tPA, although toxic to the gray matter, rescues 
white matter from ischemia independently of its proteolytic activity. These studies reveal a 
novel mechanism of action of tPA and unveil OL as a target cell for cytokine effects of tPA in 
brain diseases. They show overall that tPA protects white matter from stroke-induced lesions, 
an effect which may contribute to the global benefit of tPA-based stroke treatment.
© 2011 Correa et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e Cytokine effect of tPA in ischemic white matter | Correa et al.
formation and plasticity (Frey et al., 1996; 
Baranes  et  al.,  1998).  In  pathological 
conditions, this serine-protease can have 
detrimental as well as beneficial effects   
(Benchenane et al., 2004).  Through its pro-
teolytic activity, tPA enhances neuronal 
death by increasing Ca2+ entry through 
the N-methyl-d-aspartate (NMDA) re-
ceptor (Nicole et al., 2001) and pro-
moting laminin-dependent anoikis (Chen and Strickland, 
1997). In contrast, independently of its protease activity, it can 
protect neurons from oxidative stress (Kim et al., 1999) and 
serum deprivation–induced apoptosis (Liot et al., 2006) or 
it can contribute to microglial activation by binding to   
annexin II (Siao and Tsirka, 2002).
Earlier studies demonstrated that tPA expression and activity 
in the cerebral parenchyma decrease during aging, which results 
in reduced gray matter ischemic lesions (Roussel et al., 2009). 
animal studies focusing more closely on white matter isch-
emic lesions are warranted.
In this context, clot lysis by the intravenous injection of 
recombinant tissue plasminogen activator (tPA; Actilyse) remains 
the only approved treatment for acute cerebral ischemia. 
Originally described as a circulating serine-protease, tPA is   
also expressed within cerebral gray matter by neurons, astro-
cytes, and microglia (Rogove and Tsirka, 1998; Docagne et al.,   
1999) and plays various roles primarily related to synaptic   
Figure .  Aging differentially influences 
gray and white matter susceptibility to 
stroke. (a and b) C57/BL6 mice (4, 9, and 20 mo 
old) were subjected to permanent MCAO. Tissue 
sections were stained with thionin and lesion 
volumes were quantified in gray matter (cortex; 
a) and white matter (corpus callosum; b) 24 h 
after the onset of ischemia (mean + SEM; n = 
5–11). *, significantly (P < 0.05) different from 
4-mo-old mice, Mann-Whitney U test.(c) Repre-
sentative thionin-stained tissue sections from 
mice subjected to MCAO at different ages. 
White arrows show white matter lesions, and 
gray arrows show gray matter lesions. Bar,  
1 cm. The bottom shows gray matter lesion 
(gray arrow) in 4-mo animals at a higher mag-
nification. Note the absence of lesion in the 
white matter (white arrow). Stm, striatum; cc, 
corpus callosum; ctx, cortex (n = 5–11). Bar 
(bottom), 0.25 cm. (d) Representative image  
(n = 3) of colocalization of collagen IV immuno-
staining (red) with lectin-FITC (green) in the con-
tralateral and ipsilateral corpus callosum 24 h 
after permanent MCAO in 4-mo-old mice. Bar, 
100 µm. (e and f) Representative image (n = 3) 
of thionin staining (e) and APC immunostaining  
(f; green) and DAPI staining (f; blue) in the con-
tralateral and ipsilateral corpus callosum 24 h 
after permanent MCAO in 9-mo-old mice. Bars: 
(e) 100 µm; (f) 1 cm. (g) Quantification of OLs 
(APC+) in the contralateral and ipsilateral corpus 
callosum after permanent MCAO in 9-mo-old 
mice (mean + SEM, n = 3). *, significantly (P < 
0.05) different from contralateral, Mann-Whitney 
U test. (h) Representative image (n = 3) of  
TUNEL staining, APC immunostaining, and  
active caspase 3 immunostaining in the contra-
lateral and ipsilateral corpus callosum 24 h 
after permanent MCAO in 9-mo-old mice. Lines 
show corpus callosum limits. Bars, 100 µm.JEM Vol. 208, No. 6 
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RESULTS
Aging differentially influences gray  
and white matter susceptibility to stroke
Recent  studies  suggest  that  age-related 
changes in central nervous system tissues 
could  influence  white  matter  injuries 
(Wasserman and Schlichter, 2008; Baltan, 2009). Although this 
likely corresponds to an important aspect of human stroke 
pathology  (Baltan,  2009),  no  study  directly  addressed  this 
question in animal models of stroke. Our first step was thus to 
perform permanent middle cerebral artery occlusion (MCAO) 
in mice at three different ages (4, 9, and 20 mo) and assess the 
ischemic lesion volume in the gray matter (cortex) and in the 
white matter (corpus callosum). At 4 mo, MCAO induced 
extended lesions to the cortical gray matter (Fig. 1, a and c). 
Nevertheless,  barely  any  lesion  was  detectable  by  thionin 
staining in the white matter of 4-mo-old animals (Fig. 1, b 
and c), despite a loss of perfusion to the corpus callosum as 
shown by in vivo lectin-FITC angiography coupled to colla-
gen IV staining (Fig. 1 d). However, although gray matter 
lesion volume decreased with age (Fig. 1, a and c), as already 
reported in other models of ischemia (Shapira et al., 2002; 
Roussel et al., 2009), the damages to white matter after 
MCAO were increased (Fig. 1, b and c). White matter lesions 
were more severe in the anterior part of the corpus callosum, 
remained isolated from gray matter lesions (Fig. 1 e), and were 
characterized by loss of OLs, as assessed by immunostaining 
for the OL marker APC (Fig. 1 f) and corresponding quantifica-
tion (Fig. 1 g). OLs within white matter lesion presented features 
of apoptotic cell death, such as immunoreactivity for active cas-
pase-3 (Fig. 1 h). TUNEL staining was also detected in the same 
regions (Fig. 1 h). MCAO also induced a dramatic loss in OL 
progenitor cells, as assessed by immunostaining for PDGFR- 
(Fig. S1 a) and corresponding quantification (Fig. S1 b).
tPA is present in OLs of the corpus callosum  
and its expression is decreased with age
tPA expression has been largely reported in cells of the gray 
matter (Rogove and Tsirka, 1998; Docagne et al., 1999). 
However, little is known concerning the properties of tPA in 
cerebral white matter. The first objective of the present study 
was  to  determine  how  aging  can  influence  the  extent  of 
white matter ischemic lesions and to understand if tPA can 
affect these lesions.
Oligodendrocyte (OL) cell death occurs in acute brain 
diseases such as cerebral ischemia (Pantoni et al., 1996), 
perinatal  hypoxia-ischemia  (Ness  et  al.,  2001),  or  head 
trauma (Raghupathi, 2004), where it is an important fea-
ture of white matter lesions. OL death has been attributed 
to vulnerability to oxygen free radicals (Husain and Juurlink, 
1995),  overactivation  of  glutamate  receptors  (Sánchez- 
Gómez et al., 2003), or trophic factor deprivation (TFD; 
Molina-Holgado et al., 2002), all of which induce apopto-
sis (Matute et al., 2006; Butts et al., 2008). TFD-induced 
apoptosis has been used to reproduce features of brain cell 
injury which can be observed in pathological conditions. 
For example, loss of trophic signals can occur in the white 
matter as a consequence of ischemia. In neurodegenerative 
and demyelinating diseases, injured axons may also be less 
efficient at producing trophic molecules for cells of the 
oligodendroglial  lineage.  In  all  these  cases,  apoptosis  of 
OLs may likely result, thus contributing to the white mat-
ter lesions. Indeed, Shibata et al. (2000) reported that cas-
pase-mediated apoptosis was responsible for the death of 
OLs in hypoxic conditions and in cerebral ischemia (Shibata 
et al., 2000).
The second general objective of the present study was to 
find out whether tPA could influence OL apoptosis in vitro 
and white matter ischemic lesions in vivo. We attempted to 
uncover the molecular mechanisms sustaining this potential 
effect and, in particular, identify the membrane receptors and 
signaling pathways involved.
Figure .  tPA is expressed in OLs of the corpus 
callosum. (a) Zymography assay shows tPA activity 
in the cortex and white matter (corpus callosum) of 
4-mo-old mice (representative image of n = 3). 
Protein extracts from tPA/ cortex and corpus 
callosum appear as a negative control. (b) Photo-
micrographs of 4-mo-old mice tissue sections show 
tPA (red, left) or APC (green, middle) immunoreac-
tivities as well as merged image (right). The top (low 
magnification) shows tPA immunoreactivity is  
detected in the mossy fiber tract of the hippocampus 
(hip.), fimbria (fb.), and corpus callosum (cc.). The 
bottom (higher magnification) shows that tPA 
immunoreactivity is colocalized with APC immuno-
reactivity in the OLs of the corpus callosum (arrow-
heads; representative image of n = 3). Cytokine effect of tPA in ischemic white matter | Correa et al.
An earlier study from our group 
showed that the expression of tPA 
decreases gradually with age in dif-
ferent areas of the brain (Roussel et al., 
2009). However, these changes were 
not directly addressed in the white 
matter.  In  this  study,  a  series  of   
immunostainings was performed to 
compare the localization of tPA im-
munoreactivity in the corpus callo-
sum of young (4 mo old) and old   
(9 mo old) mice. We observed that 
the colocalization between tPA and 
APC immunoreactivities was lost in 
old  mice  (Fig.  3  a).  However,  tPA 
was still detected at this age, although 
only associated with vessels, as shown 
by double immunostaining for tPA 
and collagen IV (Fig. 3 b). A triple 
immunostaining for tPA, APC, and 
collagen  IV  (Fig.  3  c)  confirmed 
these data by showing that in young 
mice tPA is found in both OLs and 
vessels, whereas in old mice tPA ap-
pears only in vessels.
tPA protects cultured OLs from apoptotic cell  
death induced by TFD independently of its  
interaction with its known partners
Results presented in the previous section show that during aging 
in mice, tPA immunostaining is lost in OLs of the white matter, 
whereas this structure shows a greater susceptibility to stroke. 
This is in opposition to what was reported in the gray matter, 
where the decrease in tPA expression was associated with smaller 
ischemic lesions (Wang et al., 1998; Roussel et al., 2009). To ex-
plain this difference, we hypothesized that tPA could act on the 
Nevertheless,  its  expression  in  the  white  matter  remains   
undocumented. In this study, we observed using casein-
plasminogen zymography that tPA activity was not only present 
in the cerebral gray matter (Fig. 2 a, cortex) but also in the 
white matter (Fig. 2 a, corpus callosum) of young mice (1–2 
mo). Coimmunostainings for tPA and APC showed that OLs 
are the main cell type expressing tPA immunoreactivity in the 
corpus callosum of these mice (Fig. 2 b). No tPA immuno-
staining was observed in OL progenitors or microglia of the 
corpus callosum (Fig. S2, b and c).
Figure .  tPA expression in the white 
matter is altered with age. (a–c) Photo-
micrographs from 4- and 9-mo-old C57/bl6 
mice tissue sections show representative 
images of tPA (a, b, and c, red), APC  
(a, green; c, blue), and collagen IV (b and  
c, green) immunoreactivities in the corpus 
callosum of young (4 mo) and old (9 mo) 
mice. Filled arrowheads show colocalization 
of tPA and APC immunoreactivities. Empty 
arrowheads show tPA immunostaining not 
associated with vessels. Asterisks show co-
localization of tPA and collagen IV immuno-
stainings. (representative images, n = 3).  
(d and e) Quantification of OLs expressing 
tPA (APC+/tPA+; d) and total number of OLs 
(APC+; e) in the corpus callosum of young 
(4 mo) and old (9 mo) mice (mean + SEM; 
n = 3). #, significantly (P < 0.05) different 
from 4-mo-old mice, Mann-Whitney U test.JEM Vol. 208, No. 6 
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certain effects through its lysine binding sites (LBSs) or by 
binding to membrane receptors such as low-density lipoprotein 
receptor–related protein (LRP; Benchenane et al., 2005) or 
NMDA receptors (Nicole et al., 2001), or interaction with 
Annexin II (Lee et al., 2007). rhtPA was incubated with inhibi-
tors of these interactions before testing in the OL apoptotic 
model. Although NMDA receptors have been identified on 
OLs (Salter and Fern 2005), MK-801, a potent antagonist of 
NMDA receptor, did not modify the effects of rhtPA on OL 
survival (Fig. 4 f). Similarly, incubation of rhtPA with receptor-
associated protein (RAP), an antagonist of its interaction with 
the LRP, had no effect on the rhtPA action in this assay (Fig. 4 f  ). 
Last, -aminocaproic acid, which is known to antagonize po-
tential interactions with LBS of tPA, also failed to reverse the 
effects of tPA (Fig. 4 f). These data show that the antiapoptotic 
effects of tPA on OLs occur regardless of its proteolytic activ-
ity or interactions with LBS, and of its known abilities to bind 
to certain receptors such as NMDA receptors or LRP.
tPA mediates its antiapoptotic effects through an epidermal 
growth factor (EGF)–like effect
Among other structural motifs, tPA contains a domain of signif-
icant homology with the cytokine EGF. We hypothesized that 
cells of the gray and white matter in different fashions. We thus 
investigated whether tPA could influence the survival of OLs.
We used a model of apoptotic death of OLs through TFD. As 
seen in Fig. 4 a, TFD induced cell body shrinkage and loss of cell 
processes. Nuclear staining with Hoechst 33258 detected chro-
matin condensation in OLs (Fig. 4 a). This paradigm induced 
20% of cell death after 24 h (Fig. 4 b), which is in accordance 
with previous observations in this (Molina-Holgado et al., 2002) 
and other (Sánchez-Gómez et al., 2003) models of apoptotic OL 
death. Cell death was reversed by addition of a caspase 3 inhibitor 
(Fig. 4 b), confirming that OL death occurred through apoptosis 
in conditions of TFD. Interestingly, in the presence of 0.2– 
20 µg/ml of recombinant human tPA (rhtPA), TFD-induced 
OL death was reduced by 70% (Fig. 4 c). The same paradigm 
was tested on primary cultures of human OLs, which reached 
20% of cell death at 72 h (Fig. 4 d). Like in mouse cells, rhtPA 
induced a protective effect in human OLs (Fig. 4 d).
Next, we attempted to identify the mechanisms underlying 
the antiapoptotic effects of tPA in OLs. tPAstop is a competi-
tive inhibitor of tPA proteolytic activity that is known to pre-
vent  tPA-induced  potentiation  of  excitotoxic  neuronal 
death (Liot et al., 2004). However, tPAstop did not reverse the 
antiapoptotic effects of rhtPA in OLs (Fig. 4 e). tPA can mediate 
Figure .  tPA protects mouse and human 
cultured OLs from apoptotic cell death 
induced by TFD independently of its clas-
sical receptors. (a) Cultured mouse OLs were 
deprived of trophic factors for 24 h. Photo-
micrographs show representative fields after 
A2B5 immunostaining (green) and Hoechst 
33258 nuclear costaining (blue). Filled arrow-
head, A2B5 cell lacking cell processes; empty 
arrowhead, A2B5 cell lacking cell processes 
and chromatin condensation (representative 
image, n = 3). Bar, 100 µm. OL death (percent-
age) was estimated by measuring the LDH 
release in the media. (b and c) Mouse OL 
death was estimated after 24 h of TFD (black 
bar) and cotreatment with 50 or 100 µM cas-
pase 3 inhibitor (Ac-DEVD-CHO; b, gray bars; 
mean + SEM; n = 12.) or 0.2–20 µg/ml tPA  
(c, light gray bars; mean + SEM; n = 12).  
(d and e) Human OL death (percentage) was 
estimated after 72 h of TFD (black bar) and 
cotreatment with increasing doses of tPA 
(0.2–20 µg/ml; d, light gray bars; mean + 
SEM; n = 12) in the presence (e, dark gray bar) 
or absence (e, light gray bar) of 1 µM of the 
inhibitor of proteolytic activity of tPA, tPAS-
top (mean + SEM, n = 12). (f) Mouse OL death 
(percentage) was estimated after 24 h of TFD 
(black bar) and cotreatment with 10 µg/ml tPA 
in the presence (dark gray bars) or absence 
(light gray bar) of the following drugs, as 
indicated: MK801, RAP, and ACA (mean + 
SEM; n = 8, three independent plates).  
*, significantly (P < 0.01) different from TFD. Cytokine effect of tPA in ischemic white matter | Correa et al.
70-kD band revealed by peroxidase-coupled avidin (Fig. 5 a) 
at the same molecular mass as that of biotinylated rhtPA run in 
parallel (Biot tPA). This protein was absent in untreated cells 
(control). In parallel, the immunoprecipitated material showed a 
band at >150 kD corresponding to EGFR, when revealed with 
anti-EGFR antibodies (Fig. 5 a). These data show that tPA and 
EGFR are part of a same protein complex in OLs.
this domain could be responsible for the antiapoptotic effects of 
tPA. It was thus crucial to determine if tPA could interact with 
EGF receptor (EGFR). To address this issue, OLs were treated 
with  biotinylated  rhtPA,  followed  by  extraction  of  proteins 
which were then subjected to immunoprecipitation using an 
anti-EGFR antibody (Fig. 5 a). Presence of biotinylated rhtPA 
was detected in the EGFR-immunoprecipitated proteins as an 
Figure .  tPA interacts with and activates 
EGFR to mediate its antiapoptotic effects 
in OLs. (a) 50 µg of total proteins from lysates 
of untreated (control) or biotinylated tPA 
(Biot-tPA)–treated mouse OLs (10 µg/ml) or 
purified Biot-tPA were subjected to immuno-
precipitation using anti-EGFR antibody followed 
by detection with either peroxidase-coupled 
avidin (Avidin perox) or with anti-EGFR antisera 
(EGFR). As a control, the same procedure was 
performed by omitting the anti-EGFR antiserum 
(No Ab). Representative images of immunoblots 
from three individual experiments are presented. 
Numbers indicate molecular mass of standard 
proteins in kilodaltons. Single chain or double 
chain forms of tPA are indicated as sctPA or 
dctPA, respectively. (b) Cultured mouse OLs were 
treated with 10 µg/ml tPA for 24 h or not 
treated (control). Photomicrographs show 
representative fields after A2B5 (green) and 
phosphorylated EGFR (red) immunostaining or 
the merged images. (c) The phosphorylated 
form of EGFR was immunodetected in 20 µg of 
total proteins from OLs subjected to TFD in the 
presence of 10 µg/ml tPA for the indicated 
length of time. Anti–-tubulin was used as a 
control. Representative images from three 
individual experiments are presented. Bar,  
50 µm. (d–g) Mouse OL death (percentage) was 
estimated by measuring the LDH release in the 
media after 24 h of TFD (black bar). (d) Cotreat-
ment with 10 µg/ml tPA (light gray bar) in the 
presence of 0.25–5 µM AG1487 (dark gray 
bars; mean + SEM; n = 12). * and **, signifi-
cantly different from TFD, P < 0.05 and P < 
0.01, respectively; #, significantly different from 
1 µM AG1487 cotreatment, P < 0.05.  
(e) Cotreatment with 10 ng/ml EGF with or 
without an inhibitor of the kinase activity of  
5 µM EGFR (AG1487; mean + SEM; n = 8, three 
independent plates). #, significantly different 
from TFD + EGF, P < 0.05. (f) Cotreatment with 
10 µg/ml of rat recombinant WT or EGF 
domain–deleted (EGF) tPA (f) or cotreatment 
with 1–50 µg/ml of a recombinant peptide 
corresponding to the EGF domain of tPA  
(rEGF domain) or protein from uninduced  
bacterial cultures (uninduced) as a control  
(g; mean + SEM; n = 8, three independent 
plates). *, significantly (P < 0.05) different  
from TFD; #, significantly (P < 0.05) different from TFD + wttPA. (h) Diagram of the different mutant forms of tPA used in this study. (i) Mouse neuronal 
death (percentage) was estimated by measuring the LDH release in the media after 24 h of serum deprivation (black bar) and cotreatment with 20 µg/ml tPA 
(light gray bar) with or without 5 µM AG1487 (dark gray bars; mean + SEM; n = 12). **, significantly different from TFD, P < 0.01.JEM Vol. 208, No. 6 
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of rhtPA on OLs during TFD in a dose-dependent manner, 
whereas it showed no effect when applied alone (Fig. 5 d) al-
though tPA mRNA expression and a moderate tPA activity 
were detected in OLs (Fig. S4). Similarly, 10 ng/ml of recombi-
nant  mouse  EGF  protected  OLs  against TFD-induced  cell 
death, an effect which was reverted by AG1487 (Fig. 5 e). To 
further confirm that the EGF-like domain of tPA could be re-
sponsible for its antiapoptotic effect in OLs, we constructed two 
recombinant proteins, one in which the EGF-like domain of 
tPA (aa 79–117) was deleted (Fig. 5 h, EGFtPA) and a second 
one corresponding to the EGF-like domain of tPA (Fig. 5 h, 
rEGFdomain). Interestingly, the antiapoptotic effect of tPA   
We then investigated whether this interaction could in-
duce the activation of EGFR. In the presence of 10 µg/ml 
rhtPA, EGFR on the OLs appeared to be phosphorylated as 
detected by immunoblotting and immunohistochemistry   
using antisera against phospho-tyr1068 of the EGFR (Fig. 5, 
b and c). Increased phosphorylation of EGFR occurred as early 
as within 5 min of rhtPA treatment and went back to control 
levels at 60 min (Fig. 5 c and Fig. S3 show quantification).
Next, we investigated whether the interaction of tPA with 
EGFR, and the subsequent activation of this receptor, could be 
responsible for the antiapoptotic effect of tPA on OLs. Interest-
ingly, the inhibitor of EGFR kinase, AG1487, reversed the effect 
Figure .  Antiapoptotic effect of tPA is 
driven by the recruitment of Erk/ and 
Akt intracellular pathways and targets 
antiapoptotic pathways. (a) Immunodetec-
tion of phosphorylated forms (denoted with a 
prefix, p) of Akt, Erk1/2, or SapK/Jnk in 20 µg 
of total proteins from lysates of OLs subjected 
to TFD in the presence of 0.2–20 µg/ml tPA at 
24 h. Anti–-tubulin was used as a control. 
Representative images of three independent 
experiments are presented. (b) 20 µg of total 
proteins from OLs subjected to TFD in the 
presence of 10 µg/ml tPA at indicated times 
(minutes) were subjected to immunoblotting 
and detection of pAkt and pErk1/2. Anti– 
-tubulin was used as a control. Representa-
tive images from three independent 
experiments are presented. (c and d) Cultured 
mouse OLs were treated with 10 µg/ml tPA for 
24 h. Photomicrographs show representative 
fields after A2B5 (green) and phosphorylated 
Akt (c, red) or phosphorylated Erk1/2 (d, red) 
immunostaining or the merged images as 
indicated. Bars, 50 µm. (e–h) Mouse OL death 
(percentage) was estimated by measuring the 
LDH release in the media after 24 h of TFD 
(black bars) or cotreatment with 10 µg/ml tPA 
(light gray bars) in the presence of inhibitors 
(dark gray bars) of PI3/Akt (100 nM wortman-
nin; e) and Erk1/2 (10 µM PD98059; f), SapK/
Jnk (10 µM SP600125; g), or both wortmannin 
and PD98059. (h; mean + SEM; n = 12).  
*, **, and ***, significantly (respectively, P < 
0.05, P < 0.01, and P < 0.005) different from 
TFD; #, ##, and ###, significantly (respectively,  
P < 0.05, P < 0.01, and P < 0.005) different 
from TFD + tPA; NS, nonsignificant (P ≥ 0.05).  
(i) Immunodetection of Bad, Bax, Bcl-2 or  
Bcl-XL in 20 µg of total proteins from lysates 
of OLs subjected to TFD in the presence of  
10 µg/ml tPA with or without 5 µM of EGFR 
kinase inhibitor (AG1487) or 10 ng/ml EGF 
with or without 5 µM of EGFR kinase inhibitor 
(AG1487) as indicated. Anti–-tubulin was used as a control. Representative images from three individual experiments are presented. (j) Caspase-3 cysteine-
protease activity (Abs at 405 nm) in extracts (50 µg total proteins /condition) from OLs (control) or OLs subjected to TFD for 24 h, without (black bar)  
or with (light gray) 10 µg/ml tPA, as determined using a commercial kit. (Mean + SEM, n = 7, corresponding to three independent plates). *, significantly 
(P < 0.005) different from TFD; #, significantly (P < 0.005) different from control. Cytokine effect of tPA in ischemic white matter | Correa et al.
phoinositide 3 kinase (PI3K)/Akt. In addition, the PI3K–Akt 
pathway  has  previously  been  implicated  in  OL  survival   
(Vemuri and McMorris, 1996). Moreover, Tyr1068 in EGFR, 
the residue phosphorylated upon tPA treatment, is involved in 
the transduction of EGF signal through Erk and Akt pathways 
(Rojas et al., 1996). Hence, the possible activation of these 
pathways subsequent to tPA treatment in OLs subjected to TFD 
was examined. Addition of 0.2–20 µg/ml rhtPA induced the 
phosphorylation of both Akt and Erk1/2 in a dose-dependent 
manner, whereas it reduced the phosphorylation of Sap/Jnk, a 
member of the MAPK family (Fig. 6 a; and Fig. S5, a–c for cor-
responding quantifications). Activation of Akt and Erk1/2 by 
tPA treatment occurred within five minutes (Fig. 6 b; and Fig. S5, 
d and e for corresponding quantifications). Specificity of the cel-
lular location of the phosphorylated forms of Akt and Erk1/2 
was confirmed by immunocytochemistry (Fig. 6, c and d). 
was abrogated when its EGF domain was deleted (Fig. 5 f, 
EGFtPA). In contrast, 1–50 µg/ml of the rEGF peptide, when 
applied to OLs in conditions of TFD, induced antiapoptotic   
effects (Fig. 5 g), albeit with lower efficiency than native tPA. 
Finally, tPA was also able to induce antiapoptotic effects in 
neurons (Fig. 5 i), as previously described (Liot et al., 2006), 
and these effects were also reversed by AG1487 (Fig. 5 i). 
These data show that the antiapoptotic effects of tPA are 
mediated by a direct interaction with EGFR and its subse-
quent activation.
tPA, via extracellular regulated kinase (Erk) / and Akt 
intracellular pathways, regulates the balance between pro-  
and antiapoptotic factors and reduces the activity of caspase 
EGFR is able to recruit several signaling cascades, includ-
ing  mitogen-activated  protein  kinase  (MAPK)/Erk  or  phos-
Figure .  tPA injection reduces ischemic 
white matter lesions in aged mice inde-
pendently of its proteolytic activity. (a and  
b) C57/bl6 mice (9 mo old, five mice per group) 
were subjected to permanent MCAO 3 h be-
fore an intravenous injection of recombinant 
tPA (Actilyse) in its intact form (tPA) or com-
plexed with the inhibitory peptide, GGACK 
(GGACK tPA), or corresponding vehicle. Tissue 
sections were stained with thionin and lesion 
volumes were estimated in gray matter (cor-
tex; a) and white matter (corpus callosum; b) 
24 h after the onset of ischemia (mean + 
SEM, n = 5–11). * and **, significantly (respec-
tively, P < 0.05 and P < 0.01) different from 
vehicle, Mann-Whitney U test. (c) Representa-
tive thionin-stained tissue sections from mice 
subjected to MCAO. White arrows show white 
matter lesions, and gray arrows show gray 
matter lesions. Bar, 1 cm. (d) Photomicro-
graphs of tissue sections from 9-mo-old mice 
show MAP-2 (red) or APC (green) immuno-
reactivities, as well as merged images in corpus 
callosum in the indicated conditions. Control 
animals, MCAO (ipsilateral hemisphere) with 
or without i.v. injection of recombinant tPA 
(Actilyse). Demarcations show the limits of 
corpus callosum. Bar, 100 µm. Note the loss of 
both MAP-2 and APC staining after MCAO in 
vehicle-injected animals. In tPA-injected 
MCAO animals, only MAP-2 staining is lost, 
whereas APC staining is preserved. (e) Quanti-
fication of OLs (APC+) in the contralateral and 
ipsilateral corpus callosum after permanent 
MCAO in 9-mo-old, vehicle, or tPA-injected 
animals. *, significantly (P < 0.05) different 
from contralateral; #, significantly (P < 0.05) 
different from vehicle, ipsilateral Mann-Whitney 
U test. (f) C57/bl6 mice (9 mo old, five mice 
per group) were subjected to permanent MCAO 15 min before an intracerebral injection of recombinant rat tPA, recombinant EGFtPA, or corresponding 
vehicle. Tissue sections were stained with thionin and lesion volumes were estimated in white matter (corpus callosum) 24 h after the onset of ischemia 
(mean + SEM; n = 4–6). *, significantly (P < 0.05) different from vehicle, Mann-Whitney U test. (g) Representative thionin-stained tissue sections from 
mice subjected to MCAO and indicated stereotaxic injections. Bar, 1 cm.JEM Vol. 208, No. 6 
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(Nicole et al., 2001), as this effect was no longer observed 
when the enzymatic activity of tPA was blocked by the in-
hibitory peptide GGACK (Fig. 7, a and c). In sharp contrast, 
white matter lesions (Fig. 7, b and c) and loss of APC+ cells 
(Fig. 7, d and e) were reduced by the injection of rhtPA, 
results which emphasize the protective effects of tPA on white 
matter tissues. No effect of tPA administration was observed 
on microglial response within the injured white matter (Fig. S6, 
a–c). Myelin integrity was also conserved after tPA injection 
in MCAO and control animals (Fig. S6 d). Strikingly, and 
in accordance with what we described in this paper in the 
in vitro model of OL cell death, tPA exerted this action inde-
pendently of its protease activity, as GGACK-tPA was as effective 
as the proteolytically active rhtPA in reducing white matter 
lesions (Fig. 7, b and c). When injected directly into the corpus 
callosum, tPA also reduced white matter lesions induced by 
MCAO (Fig. 7, f and g). Noticeably, the deletion of EGF   
domain invalidated this protective action, as the stereotaxic 
injection of EGFtPA did not modify white matter lesion 
volume after MCAO (Fig. 7 f  ).
Finally, MCAO was induced in tPA/ mice (Carmeliet 
et al., 1994) and lesion volumes were compared with WT ani-
mals. Lesion volume was reduced in the gray matter of tPA/ 
animals (not depicted), as previously reported (Nagai et al., 
1999; Roussel et al., 2009). However, white matter lesion vol-
ume was unchanged in tPA/ as compared with WT animals 
(unpublished data).
DISCUSSION
We report in this paper that cytokine effects of tPA protect 
white matter from age-dependent stroke lesions based on the 
following observations: (1) tPA expression is decreased along 
aging in the white matter; (2) this decrease accompanies the 
emergence of a vulnerability of white matter to ischemia;   
(3) tPA plays an antiapoptotic role in OLs, the survival of 
which is critical for white matter integrity; (4) this antiapoptotic 
action is mediated through an EGF-like effect; and (5) when 
injected into aged animals, tPA drastically reduces ischemic 
lesions to the white matter. This study emphasizes aging as a 
critical factor for stroke-induced white matter lesions. Indeed, 
young animals (4 mo) hardly show any white matter lesion 
after  permanent  MCAO.  But  in  older  animals  (>9  mo),   
lesions to the white matter become evident. Considering these 
results, the use of young animals in most experimental studies 
may have put a strong brake on research on white matter   
lesions in cerebral ischemia. The use of aged animals could 
then represent a relevant approach and a good alternative to 
the models of white matter lesions, such as stereotaxic injection 
of vasoconstrictor molecules (Sozmen et al., 2009) or ex vivo 
models  of  oxygen  and  glucose  deprivation  (Baltan,  2009). 
This is of special interest when one considers the fact that   
aging is one of the crucial risk factors for stroke in humans.
What can then be the factors that render white matter 
susceptible to ischemia when animals grow old? Several facts 
pointed out tPA as a candidate of choice. Interestingly, the 
expression of tPA appears to be regulated by age in the central 
Moreover, pretreatment with an inhibitor of the activation of 
PI3K–Akt pathway (wortmannin; Fig. 6 e) or with an inhibi-
tor of MEK–Erk1/2 pathway (Fig. 6 f, PD98059) both par-
tially reversed the protective effect of rhtPA on OLs during 
TFD. In contrast, no effect was observed when inhibiting the 
phosphorylation of SapK/Jnk with SP600125 (Fig. 6 g). How-
ever, cotreatment with both wortmannin and PD98059 com-
pletely reversed the protective effect of rhtPA on OLs during 
TFD (Fig. 6 h). Together, these data show that the antiapop-
totic effect of tPA is driven by the recruitment of Erk1/2 
and Akt intracellular pathways.
Apoptosis is regulated by a balance between pro- and anti-
apoptotic factors that control downstream protease activity of 
effector caspase, caspase 3, and subsequent cell death. In this 
paper, we studied the expression of two proapoptotic factors 
(Bad and Bax) and two antiapoptotic factors (Bcl-2 and 
Bcl-XL) in OLs submitted to TFD, and their possible regula-
tion by tPA. We observed that TFD induced the up-regulation 
of Bad and Bax without affecting the expression of Bcl-2 or 
Bcl-XL (Fig. 6 i; and Fig. S5, f–i for corresponding quantifica-
tion), leading to an increase in the ratio between pro- and 
antiapoptotic factors.  Treatment with 10 µg/ml rhtPA brought 
Bad and Bax expression back to basal levels, whereas it induced 
the up-regulation of Bcl-2 and Bcl-XL (Fig. 6 i; and Fig. S5, f–i 
for corresponding quantification), thus reducing the ratio 
  between pro- and antiapoptotic factors. The cotreatment with 
AG1487 completely reversed these effects of rhtPA (Fig. 6 i; 
and Fig. S5, f–i for corresponding quantification). Moreover, 
EGF induced effects similar to those observed with rhtPA 
(Fig. 6 i; and Fig. S5, f–i for corresponding quantification). 
Finally, although TFD led to an increase in caspase 3 activity, 
no difference in this activity could be observed between 
control and rhtPA-treated cells (Fig. 6 j). These data show that 
EGF-like activity of tPA targets antiapoptotic pathways in 
OLs subjected to TFD.
tPA reduces ischemic white matter lesions  
in aged mice through its EGF domain,  
independently of its proteolytic activity
The results in the previous section show that tPA displays   
antiapoptotic properties in OLs (Figs. 4–6). We therefore hy-
pothesized that in old animals, where white matter lesions are 
associated with OL cell death (Fig. 1), the application of re-
combinant tPA could limit OL cell death and, thus, result in 
white matter protection.
To verify this hypothesis, we subjected 9-mo-old mice to 
MCAO and injected them intravenously with recombinant 
rhtPA (Fig. 7). This injection was performed at 3 h after the 
onset of ischemia, which fits with the window of therapeutic 
opportunity approved for rhtPA treatment in humans (Lansberg 
et al., 2009). MCAO in these animals induced both gray mat-
ter and white matter lesions (Fig. 7). The injection of rhtPA 
resulted in a potentiation of gray matter lesions (Fig. 7, a and 
c), as previously observed (Wang et al., 1998; Nagai et al., 
1999; Kilic et al., 2001). In accordance with previous studies, 
this potentiation was a result of the proteolytic activity of tPA 0 Cytokine effect of tPA in ischemic white matter | Correa et al.
increases the antiapoptotic factors Bcl-2 and Bcl-XL. These 
changes finally lead to a modification of the ratio between 
pro- and antiapoptotic factors in favor of antiapoptotic fac-
tors. These effects were mediated through EGFR activation 
and subsequent recruitment of PI3K–Akt and Erk1/2 path-
ways. Accordingly, EGF has been shown to induce anti-
apoptotic effects in various cell types through PI3K–Akt and 
Erk1/2 pathways, which can inhibit proapoptotic factors or 
activate antiapoptotic factors (Henson and Gibson, 2006).
The lack of difference in white matter lesion volume be-
tween WT and tPA/ animals contrasts with the extensive 
literature reporting phenotypes in the brain of tPA/ mice. 
However, cytokine effects of tPA were usually not addressed 
in these previous studies. For instance, reduction of gray mat-
ter lesions in tPA/ mice, reported previously (Nagai et al., 
1999; Roussel et al., 2009), is generally attributed to proteo-
lytic effects of tPA. This is in agreement with one of the gen-
eral conclusions of this study, which is that tPA differently 
affects the susceptibility of white and gray matter to stroke-
induced lesions. These differential effects account for distinct 
mechanisms of action of tPA (proteolytic vs. nonproteolytic) 
depending on the brain structure. Several hypotheses could 
explain the lack of phenotype in the ischemic white matter of 
tPA/ animals, such as putative compensatory mechanisms 
or redundancy of tPA cytokine effects to other cytokines.   
Future studies using pharmacological inhibitors or siRNA   
might be helpful to discern potential compensatory effects in the 
white matter and allow one to discern the necessity and suffi-
ciency of tPA for protection. Overall, these different points 
raise the question of the respective effects of endogenously 
produced versus exogenously delivered tPA. Although our 
study focused on the potential therapeutic effects of exoge-
nously applied tPA, further investigations should be initiated 
to better understand the role of endogenous tPA in white 
matter stroke lesions.
One essential observation was that although tPA reduces 
white matter lesions after cerebral ischemia, it exacerbates 
gray matter lesions, as was previously observed in other 
models of stroke (Benchenane et al., 2004). The latter effect 
has been attributed to a proteolytic action leading to the po-
tentiation of NMDA-mediated excitotoxic lesions (Nicole   
et al., 2001). Accordingly, in the present study, when the pro-
tease activity of tPA was blocked (GGACK-tPA), its injection 
no longer affected gray matter lesion volume. Interestingly, 
protease-inactivated tPA nevertheless remained as efficient as 
native tPA in reducing white matter damage. This is in agree-
ment with our description of a protease-independent protec-
tive effect of tPA on OLs.
To summarize these data, tPA would act as a double-edged 
sword when it enters the brain parenchyma: on the one hand, 
it induces a deleterious effect in the gray matter as a result of 
the cleavage of the NMDA receptor and subsequent potenti-
ation of excitotoxicity in neurons; on the other hand, it pro-
vides a beneficial effect in the white matter as a result of the 
activation of EGFR and subsequent protection against apop-
tosis in OLs. The present work fits with the idea that the 
nervous system, where it can influence severity of ischemia in 
an age-dependent manner (Roussel et al., 2009). Moreover, 
although white matter lesions were not addressed in this pre-
vious study, tPA has been reported to influence white matter 
physiopathology  in  experimental  models  of  nerve  injury 
(Minor et al., 2009), preterm excitotoxic lesions (Hennebert 
et al., 2004), or multiple sclerosis (Lu et al., 2002), for instance. 
However, how tPA can influence the outcome of white mat-
ter tissues after stroke was unknown, and study of these effects 
appears to be mandatory when one considers that tPA is the 
only approved treatment for acute stroke in humans.
The present study is the first to address the effect of tPA 
on apoptosis in OLs, and it concludes that tPA has antiapop-
totic properties on these cells. This contrasts with earlier stud-
ies in neurons, in which tPA exacerbates excitotoxic death 
and displays proapoptotic (Flavin et al., 2000; Liu et al., 2004) 
and antiapoptotic (Liot et al., 2006; Lee et al., 2007) effects. 
These opposite effects may explain why, when injected into 
mice subjected to MCAO, tPA aggravates gray matter lesions, 
whereas it reduces white matter lesions (Fig. 7).
Although most of the functions of tPA are driven by its 
serine-protease activity, growing evidence indicates that non-
proteolytic activities are also important (Yepes et al., 2009). 
The present study shows for the first time that independently 
of its proteolytic activity, but by binding to and subsequently 
inducing phosphorylation of EGFR, tPA can induce anti-
apoptotic effects in OLs. Overall, our study suggests that by 
the virtue of its EGF-like domain, tPA could substitute the 
classical trophic molecules, such as cytokines or growth fac-
tors, and promote survival of OLs. Consequently, the pro-
survival action of tPA would be redundant of other cytokines, 
which suggests that tPA can, in certain conditions, be regarded 
as a component of the cytokine network.
Two earlier studies linked tPA to EGF signaling (Hurtado 
et al., 2007; Ortiz-Zapater et al., 2007), although in a different 
process (proliferation), in a different cell type (pancreatic cells), 
and by the following different mechanisms: (1) tPA, via the 
sequential action of plasmin and metalloproteinase 9 can acti-
vate heparin-bound EGF into free EGF, leading to subsequent 
EGF signaling (Hurtado et al., 2007); and (2) tPA can induce 
its action through binding to EGFR (Ortiz-Zapater et al., 
2007) but, in contrast to our results, dependently of Annexin 
A2. These different data underline the variety that exists in 
the mechanisms of action of tPA, depending on the biological 
context in which this molecule is found.
Several  paradigms  of  OL  cell  death  have  been  used   
in vitro, such as nitric oxide toxicity (Baud et al., 2004), hyper-
oxia (Gerstner et al., 2006), excitotoxicity (Sánchez-Gómez 
et al., 2003), or growth factor deprivation (Molina-Holgado 
et al., 2002), all of which induce apoptosis. Remarkably, de-
spite the variety in the nature of compounds displaying anti-
apoptotic properties in these models, one common factor in 
their mechanisms of action is the activation of the PI3K–Akt 
pathway, as also observed in the present study (Fig. 6).
In this study, we show that in conditions of TFD, tPA re-
duces the levels of the proapoptotic factors Bad and Bax and JEM Vol. 208, No. 6 
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directed against tPA (rabbit anti-tPA, 1:1,500; gift from H.R. Lijnen, Center 
for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium; 
Declerck et al., 1995; Roussel et al., 2009; Baron et al., 2010), APC (Mouse 
monoclonal anti-APC, 1/600; ab16794; Abcam), type IV collagen (goat anti–
collagen IV, 1:1,500; SouthernBiotech), PDFGR- (rat anti-CD140a, 1:800; 
BD), or different combinations of these antibodies. Potential unspecific stain-
ing with tPA antibody was blocked by pretreating this antibody with tPA/ 
protein extracts. The following protocol was used to perform this blockade: 
brains from tPA/ animals were isolated and frozen. A tissue suspension was 
then obtained by dissociation in saline before incubation at 4°C for 5 min. 
After treatment with acetone (4:1) and vigorous shaking, the precipitate was 
recovered by centrifugation at 10,000 g for 10 min. The precipitate was 
finally dried at room temperature until obtaining a powder. This powder was 
added to the antibody at a concentration of 1%. By using this technique, sig-
nal given by this antibody was completely shut down in tPA/ animals 
(Fig. S2 a). All our tPA immunostainings were performed using this treated 
tPA antibody. Detection was performed using donkey TRITC- or FITC-
conjugated secondary antibodies (1:500; Jackson ImmunoResearch Labora-
tories, Inc.). Sections were examined with a microscope (DM6000; Leica). 
Images were digitally captured using a camera (CoolSNAP; Photometrics) 
and visualized with MetaVue software (Molecular Devices). For each set of 
immunostaining, the following controls were systematically performed in 
adjacent sections: (1) Single immunolabeling, with omission of primary anti-
bodies: no signal detected (excludes unspecific signal given by the secondary 
antibody); (2) single immunolabeling with omission of secondary antibodies: 
no signal detected (excludes signal given by autofluorescence of the tissues); 
(3) coimmunostaining (tPA and cell markers) revealed by another set of sec-
ondary antibodies, colocalization of both immunostaining (same pattern of 
expression); (4) absence of cross-reactivity between the antibodies in multi-
immunolabeling experiments demonstrated by a set of stainings in which 
each of the primary antibodies was, respectively, omitted; (5) absence of irrel-
evant signal detection when using only the cocktail of secondary antibodies.
In vivo lectin-FITC angiography. In vivo lectin-FITC angiography was 
performed as previously described (Thiyagarajan et al., 2008). In brief, FITC-
labeled Triticum vulgaris lectin (Sigma-Aldrich) at 10 mg/kg was administered 
via the tail vein in anesthetized mice 3 h after MCAO. Mice were euthana-
tized 2 min after lectin administration and transcardiac perfusion of ice-cold 
heparinized saline was performed followed by fixation with picric acid and 
paraformaldehyde. Brains were removed and processed for immunohistologi-
cal analysis as described.
TUNEL  staining. TUNEL staining was performed from 10-µm frozen   
tissue sections using the in situ cell death detection kit fluorescein (Roche) 
according to the manufacturer’s instruction.
Image analysis and quantification. The image analysis was performed 
using ImageJ software. The total number of OLs (APC-positive cells) and tPA 
expressing OLs (APC-positive/tPA-positive cells) was determined in the ante-
rior part of the corpus callosum of healthy mice or mice subjected to MCAO 
(4 or 9 mo) immunostained for tPA and APC. All quantitative analysis was done 
in three randomly selected sections per mouse (three mice per condition).
Casein-plasminogen  zymography  assay. In brief, 5 µg of protein   
extracts were resolved on SDS–PAGE (12%) containing 1 mg/ml casein and 
plasminogen. After migration, the gel was washed in 2.5% Triton X-100 solu-
tion and incubated for 2 h in a buffer containing 100 mM glycine and 10 mM 
EDTA, pH 8.3. Light bands indicating proteolytic activity were visualized by 
Coomassie staining.
OL cell cultures. OL cell cultures were prepared as previously described 
(Molina-Holgado et al., 2002) from postnatal day 0 (P0)–P1 newborn mice 
from P0-P1 newborn mice. After 10 d in vitro, a confluent culture was ob-
tained, composed of microglia and OLs on top of a confluent monolayer of 
astrocytes. Cells were shaken at 225 rpm at 37°C for 3 h to remove microglia. 
different domains of tPA can play distinct and even opposite 
roles in the physiopathology of the brain. Hence, understand-
ing their respective functions is crucial to adapt the use of 
plasminogen activators in acute stroke management and to 
design new and more efficient molecules.
MATERIALS AND METHODS
Materials. AG1478 was obtained from Tocris Bioscience. Caspase 3 inhibi-
tor was obtained from Enzo Life Sciences. rmEGF, MK801, -aminocaproic 
acid, tPAstop, and the mouse anti–mouse -tubulin antibody were obtained 
from Sigma-Aldrich. Rabbit anti–mouse pErk1/2 and pAkt and anti–mouse 
phosphorylated EGFR antibodies were obtained from Cell Signaling Tech-
nology. Caspase 3 activity detection kit was obtained from Invitrogen. 
Anti–rabbit  IgG  antibody  was  obtained  from  Jackson  ImmunoResearch 
Laboratories, Inc. and anti–mouse IgG antibody was obtained from Bio-Rad 
Laboratories. Human rt-PA (Actilyse) was obtained from Boehringer Ingel-
heim and was dialyzed using membranes that exclude molecules with a mo-
lecular mass <10 kD. This procedure allows, in particular, the removal of 
arginine and small peptides contained in the solution. Monoclonal anti–
mouse A2B5 antibody was a gift from M. Holgado (National Hospital for 
Paraplegics, Toledo, Spain). RAP was provided by G. Bu (St. Louis Children’s 
Hospital, St. Louis, MO).
Animals and surgery. C57BL6-J mice (aged 4, 9, and 20 mo; Janvier) were 
housed in a temperature-controlled room on a 12-h-light/12-h-dark cycle 
with food and water ad libitum. Experimental protocols were approved by 
the regional committee of ethics of Lower Normandy (accredited establish-
ment  number  C14118001).  Experiments  were  performed  in  accordance 
with French ethical laws (act no. 87–848; Ministère de l’Agriculture et de la 
Forêt) and the European Communities Council Directives of November 24, 
1986 (86/609/EEC) guidelines for the care and use of laboratory animals. 
The middle cerebral artery (MCA) was permanently occluded (MCAO) by 
electrocoagulation under anesthesia with isoflurane (induction 5%, mainte-
nance 2.5% in 70/30% NO2/O2). Rectal temperature was maintained at 
37°C using a feedback-regulated heating pad. Mice were placed in a stereo-
taxic frame, the skin between the right ear and the right eye was incised, and 
the temporal muscle was carefully retracted. The MCA was exposed and per-
manently occluded by electrocoagulation. After this surgical procedure the 
skin was glued with cyanoacrylate and animals were allowed to recover. For 
in vivo tPA studies, mice were anesthetized with 3 ml after MCAO and in-
jected with a bolus of 10 mg/kg tPA, 10 mg/kg GGACK-tPA, or an equiva-
lent volume of saline through a catheter inserted into the tail vein.
For stereotaxic injections, a microinjection pipette (internal diameter 
0.32 mm and calibrated at 15 mm/µl; Hecht Assistent) was stereotaxically 
implanted in the right corpus callosum (anteroposterior, 0.2; lateral, 3; 
dorsoventral, 1.9) in anesthetized mice and left for 10 min before 2 µg tPA 
or its EGF-lacking mutein were injected in a total volume of 2 µl. The 
pipette was removed 5 min later. Thereafter, mice underwent permanent 
MCAO as described in the previous paragraph. Time between tPA injection 
and artery occlusion ranged between 15 and 18 min.
24 h after ischemia, mice were euthanized. The brains were removed and 
frozen in isopentane for histological analysis. Cryostat-cut coronal brain sec-
tions (20 µm) were stained with thionine. For volume analysis, 1 section out 
of every 10 was stained and analyzed using ImageJ (National Institutes of 
Health). The lesion volume was estimated as the sum of every lesion area 
(unstained region) for each section, multiplied by the distance between each 
section (0.2 mm).
Immunohistochemistry.  Mice  were  deeply  anesthetized  and  perfused 
transcardially with 20 ml of cold heparinized NaCl 0.9%, followed by 2% 
paraformaldehyde and 0.2% picric acid in 150 ml of 0.1 M sodium phos-
phate buffer, pH 7.4. Brains were removed, washed in veronal buffer contain-
ing 20% sucrose, and frozen in Tissue-Tek (Miles Scientific). 10-µm coronal 
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and downstream primer 5-GGCAAGCTTATCACAGCGTTTCCCAAC-3, 
thus  introducing  a  BamHI  and  a  HindIII  restriction  site  (underlined),   
respectively, for insertion in pQE100-Double Tag vector (QIAGEN), which 
provides 6xHis at the amino terminus of the insert. The cloned insert was   
sequence-verified. Recombinant peptide was purified in buffer containing 8M 
urea,  from  inclusion  bodies  of  isopropyl  1-thio--d-galactopyranoside 
(IPTG)–induced bacterial cultures (Escherichia coli, M15 strain), on a nickel 
affinity matrix as described by the manufacturer (QIAGEN). Desalting of the 
relevant fractions was performed using PD MidiTrap G-10 (GE Healthcare) 
to remove urea. The recombinant peptide corresponding to the EGF-like 
domain, thus obtained, was equilibrated and allowed to refold in PBS con-
taining Tween 80 (0.5%).
For WT tPA and EGFtPA, rat tPA sequence signal (aa 1–32) was am-
plified from the full-length Rattus norvegicus tPA cDNA (Swiss-prot accession 
P19637) using the upstream primer 5-CGGCTAGCATGAAGGGAGA-
GCTGTTG-3 and the downstream primer 5-GCGGATCCGTGATG-
GTGATGGTGATGCCGAGCTCCTCTTCT-3, thus including the NheI 
and BamHI restriction sites (underlined), respectively, and a 6xHis tag just 
before the BamHI site. PCR products were digested and inserted into the 
eukaryotic expression system pcDNA5/FRT. Coding sequence for mature 
rat WT tPA WT and EGFtPA proteins were amplified from the same tPA 
cDNA sequence by using the appropriate primers. Deletion of the EGF   
domain was obtained by fusing the PCR product corresponding to the finger 
and K1 domains of tPA with the PCR product corresponding to the protease 
domain of tPA. PCR products were inserted into pcDNA5/FRT plasmid be-
tween the BamHI and XhoI restriction sites. The various plasmids obtained 
were systematically checked by automated sequencing (GATC-Biotech). 293 
HEK FlpIn Cells (Invitrogen) were then transfected using Lipofectamine 
2000 and positive clones were isolated using a 300-µg/ml hygromycin B 
(Sigma-Aldrich)  selection.  Supernatants  containing  tPA-related  muteins 
were harvested and the proteins of interest purified on a nickel affinity   
matrix (QIAGEN) as described by the manufacturer. Elimination of imidazole 
was performed by overnight dialysis against 0.5 M ammonium bicarbonate 
buffer. After concentration using Amicon Ultra (cutoff, 10 kD; Millipore),   
recombinant proteins were subjected to zymography to assess their enzymatic 
activity and confirm their molecular mass.
Production of proteolytically inactive tPA (GGACK tPA). A fourfold 
molar excess of GGACK (1,5-dansyl-l-glutamyl-l-glycyl-l-arginine chloro-
methylketone; EMD) was added to Actilyse (Boehringer Ingelheim) and   
allowed to react for 24 h at room temperature. The resulting solution was 
dialyzed for 48 h at 4°C against PBS to remove all unbound GGACK. Argi-
nine monohydrochloride (Sigma-Aldrich) was added to GGACK-tPA to   
reconstitute Actilyse buffer. A spectrozyme assay (American Diagnostica) was 
performed to confirm the lack of proteolytic activity of GGACK-tPA.
Statistical analysis. All results are expressed as mean + SEM. For in vitro 
experiments, the n value corresponds to n different well pools derived from 
three independent dissections. Statistical analyses consisted of one-way ANOVA, 
followed by Bonferroni–Dunn’s test. Results of animal experiments were   
analyzed by Mann-Whitney’s U test.
Online supplemental material. Fig. S1 shows loss of OL progenitor cells 
in the white matter after MCAO. Fig. S2 shows that tPA immunostaining is 
absent in microglia and OL progenitor cells of white matter. Fig. S3 shows 
quantification of Western blots showing the phosphorylation of EGFR after 
tPA treatment. Fig. S4 shows tPA expression in cultured OLs. Fig. S5 shows 
quantification of Western blots for intracellular pathways and pro/antiapoptotic 
factors. Fig. S6 shows that tPA does not influence microglial response or   
myelin integrity in the white matter after MCAO. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20102555/DC1.
We are grateful to Anuradha Alahari for critical reading and editing of the 
manuscript. We would like to thank Laurent Plawinski, Joaquín Sancho, and Elisa 
Baides for their excellent technical assistance.
A second cycle of shaking was then performed (285 rpm, 37°C, overnight) 
to remove OLs from the astrocytes monolayer. The cell suspension was plated 
on bacterial grade Petri dish for 2 h to separate OLs from remaining microg-
lia. Purified OLs (1.25 × 105 cells/cm2) were cultured in DME/F12 (1:1) 
supplemented with 5 ng/ml each of recombinant PDGF-AA and bFGF and 
B27. Experiments were performed at 1 d in vitro. TFD was performed by 
switching cells to DME/F12 medium lacking PDGF-AA, bFGF, and B27.
Human cultures. Human cultures were established from brain tissues of 
aborted human brain fetuses after 10–12 wk of gestation. The protocol for 
tissues so obtained complied with institutional and national guidelines. OL 
cultures were obtained according to the same method as the one used for 
mouse cell cultures.
Neuronal  cultures.  Neuronal  cultures  were  prepared  as  previously  de-
scribed in Liot et al. (2006). Apoptosis was induced in these cells at 7 d in   
vitro by switching cells to DME medium lacking serum.
Immunocytochemistry in cultured cells. Immunocytochemistry in cul-
tured cells was performed as described previously (Molina-Holgado et al., 
2002). In brief, cells plated onto PDL-coated coverslips were incubated for   
1 h at room temperature in PBS containing 5% fetal goat serum with pri-
mary antibodies for A2B5 (1:50). After being rinsed with PBS, the cells were 
incubated for 1 h at room temperature with secondary Alexa Fluor–conjugated 
anti–mouse IgG. Then the coverslips were washed with PBS and mounted on 
slides. Nuclei were co-labeled with 1 µg/ml Hoechst 332583 for 10 min at 
room temperature. Absence of nonspecific interactions was verified by omit-
ting the primary antibodies.
Immunoprecipitation. Specific antisera were added to cell lysates and al-
lowed to react for 2 h at 4°C before adsorption to protein G–Sepharose (GE 
Healthcare). The resin was washed three times and bound proteins were 
eluted in a buffer containing DTT and -mercaptoethanol.
Immunoblotting. Cell lysates were mixed with 5× Laemmli sample buffer 
and held at 95°C for 5 min. 20 µg of proteins/condition was resolved on 10% 
SDS-PAGE and electroblotted onto nitrocellulose membrane. Membranes 
were blocked for 1 h at room temperature in 5% (wt/vol) dry skim milk in 
TBS with 0.1% Tween 20 (TBST), incubated overnight at 4°C with the 
corresponding primary antibodies as previously described (Correa et al., 
2005), and extensively washed with 5% milk-TBST solution before incuba-
tion with secondary antibodies for 1 h at room temperature. Finally, the blots 
were rinsed and the peroxidase reaction was developed by enhanced chemi-
luminescence (GE Healthcare). The blots were stripped in 62.5 mM Tris-
HCl, pH 6.8, containing 2% SDS and 0.7% -mercaptoethanol and were 
reprobed sequentially.
Quantification of cell death. OL cell death was estimated by A2B5 im-
munostaining and examination of the cultures under bright-field microscopy, 
and quantified by measurement of lactate dehydrogenase (LDH) release from 
damaged cells into the bathing medium. The LDH level corresponding to 
complete cell death was determined in sister cultures exposed to 1% Triton 
X-100 for 24 h (full kill, FK). Background LDH levels were determined 
in sister cultures subjected to sham wash (blank, BK). Percentage of cell death 
in experimental conditions was calculated using the following formula: [% of 
cell death = (experimental value  BK) × 100/(FK  BK)].
Caspase activity assay. Colorimetric detection of caspase 3 cysteine-protease 
activity in extracts of OL cultures (50 µg of total proteins/condition) was per-
formed through the use of the Apotarget commercial kit (Invitrogen).
Construction and production of recombinant proteins. For the His-
tagged EGF-like tPA-derived domain, the region of Rattus norvegicus tPA cDNA 
(Uniprot ref P19637) encoding aa 79–117 (EGF-like domain) was amplified   
using the upstream primer 5-CCGGGATCCCCCGTCCGAAGTTGC-3 JEM Vol. 208, No. 6 
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